ExoOne Bio. Co., Ltd.

Founded in December 2020 by Dr. Tzou-Yien Lin, ExoOne Bio. Co., Ltd. is a biotechnology company focused on developing innovative applications based on human exosome technology. The company initially operated from the Linkou Startup Terrace and relocated to the Taipei Bioinnovation Park in Nangang in 2023 as it expanded its research and commercialization activities. 

ExoOne Bio's core technological capabilities center on the purification, characterization and isolation of human exosomes. The company applies these technologies to the development of biological drugs and regenerative medicine solutions, with research activities targeting degenerative conditions including ophthalmic and neurological diseases as well as sarcopenia. Its exosome-based drug development program has also been recognized as an indicator case by Taiwan's Center for Drug Evaluation (CDE). 

In addition to pharmaceutical R&D, the company has expanded its exosome technology into commercial applications in aesthetic medicine, professional skincare and hair care. Its ExoMuse brand focuses on products based on umbilical cord mesenchymal stem cell-derived exosome technology and is designed primarily for aesthetic clinics, professional skincare institutions and distribution partners. 艾萬霖生技

Through this combination of proprietary exosome technologies, drug development capabilities and commercial product development, ExoOne Bio is building an integrated biotechnology platform spanning exosome R&D, regenerative medicine, pharmaceutical development, aesthetic applications and professional skincare products.